Physician profile
Ewa Vaizers
NPI 1326876236
$5,185.82
in general payments reported to CMS, 2019-2025
28 companies · $3,473 in 2025
The $3,473 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,713 · 2025: $3,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,015 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,015.02 |
| Education | $170.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,172.88 | 2024-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $744.45 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $419.26 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $391.04 | 2024-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $290.43 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Harmony Biosciences LLC | $258.43 | 2025 | |
| Grifols USA, LLC | $239.13 | 2024-2025 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $231.69 | 2024-2025 | Inspire |
| Insmed, INC. | $222.68 | 2024-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.00 | 2024-2025 | Ofev, Jascayd |
| Verona Pharma, INC. | $159.03 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $120.26 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $104.22 | 2024-2025 | Zerbaxa |
| Takeda Pharmaceuticals U.S.A., INC. | $100.82 | 2024-2025 | Glassia, Cuvitru |
| Avadel Cns Pharmaceuticals, LLC | $79.13 | 2024-2025 | Lumryz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $79.00 | 2024-2025 | Vest Therapy Und, Encore, (8874) Incourage |
| United Therapeutics Corporation | $72.29 | 2024 | Tyvaso |
| Amgen INC. | $57.68 | 2024-2025 | Tezspire, Tavneos |
| Ani Pharmaceuticals, INC. | $41.90 | 2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $39.73 | 2025 | Xolair |
| Mylan Specialty L.P. | $38.06 | 2024 | Yupelri |
| Azurity Pharmaceuticals, INC. | $31.16 | 2025 | Alvesco |
| Fisher & Paykel Healthcare INC | $29.96 | 2025 | Fisher & Paykel Healthcare |
| Electromed, INC. | $27.69 | 2025 | Smartvest |
| Lilly USA, LLC | $21.49 | 2025 | Zepbound |
| Viatris Specialty LLC | $20.31 | 2025 | Yupelri |
| Pfizer INC. | $15.21 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ewa Vaizers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.